Nektar Therapeutics
NASDAQNektar Therapeutics enters the back half of September in a bruising stretch, down nearly 12% on the week to $66.64, even as short sellers — who hold a structurally large stake — have been quietly trimming exposure through the slide. The most striking tension this week is the gap between what's happening to the stock and what's happening to its short position. With 29.2% of the free…
NKTR cost to borrow surges 586% in one week to 0.46%, though absolute rate stays minimal.
Snapshot as of 22 Sept 2026
Nektar Therapeutics enters the back half of September in a bruising stretch, down nearly 12% on the week to $66.64, even as short sellers — who hold a structurally large stake — have been quietly trimming exposure…
NKTR closed at $81.89 on Friday, down 5.3% on the week — yet the most consequential moves for the stock happened after the bell on Thursday, not during it. Q1 earnings hit on May 7 and the market was underwhelmed.…
Nektar Therapeutics heads into its May 7 first-quarter report carrying two compounding weights: a flurry of securities fraud class actions and a 10.7% weekly price decline that has tested the conviction of a Street…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for NKTR — free to start on ORTEX.
Sign up for free →Open NKTR on ORTEX